Dr Reddys Company Insiders

RDY Stock  USD 14.30  0.16  1.13%   
Dr Reddys employs about 27 K people. The company is managed by 49 executives with a total tenure of roughly 216 years, averaging almost 4.0 years of service per executive, having 552.0 employees per reported executive. Break down of Dr Reddys' management performance can provide insight into the company performance.
M Ramana  CEO
Chief Executive Officer, Branded Markets (India and Emerging Markets)
Satish Reddy  Chairman
Co-Chairman of the Board
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Dr Reddys' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Dr Reddys' future performance. Based on our forecasts, it is anticipated that RDY will maintain a workforce of slightly above 27050 employees by January 2025.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Dr Reddys Management Team Effectiveness

The company has Return on Asset of 0.104 % which means that on every $100 spent on assets, it made $0.104 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1927 %, implying that it generated $0.1927 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Dr Reddys' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.15 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 16.9 B in 2024, whereas Total Assets are likely to drop slightly above 214.9 B in 2024.
Common Stock Shares Outstanding is likely to rise to about 175.5 M in 2024. Net Income Applicable To Common Shares is likely to rise to about 54.4 B in 2024

Dr Reddys Workforce Comparison

Dr Reddys Laboratories is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 29,060. Dr Reddys totals roughly 27,048 in number of employees claiming about 93% of equities under Health Care industry.

Dr Reddys Profit Margins

The company has Net Profit Margin of 0.18 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.23 %, which entails that for every 100 dollars of revenue, it generated $0.23 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.430.5861
Way Down
Very volatile
Net Profit Margin0.210.1995
Notably Up
Slightly volatile
Operating Profit Margin0.250.2426
Fairly Up
Pretty Stable
Pretax Profit Margin0.270.2574
Sufficiently Up
Slightly volatile
Return On Assets0.150.1437
Sufficiently Up
Slightly volatile
Return On Equity0.10.1985
Way Down
Pretty Stable

Dr Reddys Laboratories Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Dr Reddys Laboratories Price Series Summation is a cross summation of Dr Reddys price series and its benchmark/peer.

Dr Reddys Notable Stakeholders

A Dr Reddys stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dr Reddys often face trade-offs trying to please all of them. Dr Reddys' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dr Reddys' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MARC KIKUCHIChief Executive Officer, North America GenericsProfile
Venkata MBACEO CouncilProfile
Patrick AghanianChief Executive Officer, European GenericsProfile
Milan KalawadiaCEO CouncilProfile
M RamanaChief Executive Officer, Branded Markets (India and Emerging Markets)Profile
Satish ReddyCo-Chairman of the BoardProfile
G PrasadCo-Chairman of the Board, Chief Executive Officer, Managing DirectorProfile
MPharm MSSenior PresidentProfile
Saumen ChakrabortyPresident, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCREProfile
Ganadhish KamatExecutive Vice President and Global Head-QualityProfile
Parag AgarwalChief Financial Officer - DesignateProfile
Erez IsraeliChief Operating Officer and Global Head of Generics & PSAIProfile
Leo PuriNon-Executive Independent DirectorProfile
Arunabha RayChaudhuriHead DirectorProfile
Prasad MenonLead Non-Executive Independent DirectorProfile
Shikha SharmaNon-Executive Independent DirectorProfile
Bharat DoshiNon-Executive Independent DirectorProfile
Bruce CarterNon-Executive Independent DirectorProfile
Allan ObermanNon-Executive Independent DirectorProfile
Sridar IyengarNon-Executive Independent DirectorProfile
Kalpana MorpariaNon-Executive Independent DirectorProfile
Krishna MSGlobal CouncilProfile
Sandeep PoddarCompliance Officer, Company SecretaryProfile
Sumera HashamSenior officerProfile
Jayanth SridharGlobal CouncilProfile
Sanjay BTechGlobal VPProfile
K KrishnanAdditional Independent DirectorProfile
Gunupati BEMD CoChairmanProfile
Raymond VreGlobal Head of BiologicsProfile
Archana BhaskarChief Human Resource OfficerProfile
Erez MBACEO CouncilProfile
MS BTechChairman CouncilProfile
Deepak SapraGlobal Head of Pharmaceutical Services and Active IngredientsProfile
Penny WanAdditional Independent DirectorProfile
P YugandharGlobal Head of Supply ChainProfile
Sushrut KulkarniGlobal CouncilProfile
Sauri GudlavalletiGlobal Head of Integrated Product Development OrganizationProfile
YUGANDHAR PUVVALAGlobal Head of Supply ChainProfile
K SinghChief Compliance Officer, Company SecretaryProfile
Anil NamboodiripadGlobal Head of Proprietary ProductsProfile
SANJAY SHARMAGlobal Head of ManufacturingProfile
Vivek MittalInterim Compliance Officer, General CounselProfile
Kumar SinghCompliance SecretaryProfile
Richa PeriwalHead AnalyticsProfile
Mannam VenkatanarasimhamDeputy CouncilProfile
Deepak MBACEO CouncilProfile
Bhethanabottla PhanimitraChief CouncilProfile
MBA MBACEO CouncilProfile
Mukesh RathiChief Digital and Information OfficerProfile

About Dr Reddys Management Performance

The success or failure of an entity such as Dr Reddys Laboratories often depends on how effective the management is. Dr Reddys management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RDY management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RDY management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.16  0.11 
Return On Capital Employed 0.23  0.24 
Return On Assets 0.14  0.15 
Return On Equity 0.20  0.10 
Please note, the imprecision that can be found in Dr Reddys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dr Reddys Laboratories. Check Dr Reddys' Beneish M Score to see the likelihood of Dr Reddys' management manipulating its earnings.

Dr Reddys Workforce Analysis

Traditionally, organizations such as Dr Reddys use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dr Reddys within its industry.

Dr Reddys Manpower Efficiency

Return on Dr Reddys Manpower

Revenue Per Employee10.3M
Revenue Per Executive5.7B
Net Income Per Employee2.1M
Net Income Per Executive1.1B
Working Capital Per Employee5.6M
Working Capital Per Executive3.1B

Additional Tools for RDY Stock Analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.